Oncolytics Biotech Inc
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Oncolytics Biotech's stock with a target price of $4.15, indicating strong growth potential.
Financial Health
Oncolytics Biotech is managing to generate cash but has a low book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ONCY
Alternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: October 13, 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage immunotherapy
Pelareorep aims to both kill tumour cells and boost anti-tumour immunity; trial readouts can materially affect prospects, though results are uncertain.
Combination therapy focus
Many studies pair pelareorep with chemo or immune checkpoint inhibitors — partnerships could de‑risk development but regulatory hurdles remain.
Speculative small-cap
Market cap near $108M implies higher volatility and potential dilution; suitable for investors who accept biotech-specific risks and long timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
